Moderna Closes $3B Convertible Note Offering, Including Full $400M Overallotment Exercise

Moderna (NASDAQ: MRNA) completed a $3 billion private offering of 0.00% Convertible Senior Notes due 2032 on Tuesday, September 1, with initial purchasers exercising their overallotment option in full to bring total proceeds to $3 billion, inclusive of the additional $400 million tranche. Shares gained 9.93% on the day while the S&P 500 declined 0.69%.

Deal Terms

• Total offering size: $3,000,000,000 aggregate principal amount of Convertible Senior Notes due March 1, 2032
• Overallotment exercised in full: Initial purchasers drew down the entire $400 million option, confirming strong demand for the offering
• Coupon: 0.00%; notes carry no regular interest, and principal will not accrete
• Special interest provision: Contingent special interest may accrue in specific circumstances defined in the indenture, payable semiannually on March 1 and September 1, beginning March 1, 2027
• Trustee: U.S. Bank Trust Company, National Association
• Security type: General senior unsecured obligations of Moderna, Inc.

Why It Matters

The zero-coupon structure means Moderna incurs no ongoing cash interest burden on the $3 billion raised, preserving liquidity while securing a long-dated capital runway through early 2032. The notes are convertible at holders' option prior to December 1, 2031 under specific conditions set out in the indenture, with the conversion mechanism providing a path to equity settlement that limits near-term dilution to current shareholders.

Moderna entered the transaction carrying $5.14 billion in total cash against $1.29 billion in existing total debt, a debt-to-equity ratio of 0.19x. The $3 billion raise materially expands the company's balance sheet capacity at a point when its pipeline investment requirements remain substantial.

Wall Street View

Wall Street's current consensus on Moderna skews toward Hold, with the most recent distribution recorded as of August 1, 2026 showing 7 Buy ratings, 18 Hold ratings, and 3 Sell or Strong Sell ratings among covering analysts. No specific analyst price-target actions tied to the note offering were available in the source data at the time of publication.

Investor Takeaway

The completion of a $3 billion zero-coupon offering, with the full overallotment exercised, indicates that institutional demand for Moderna paper remains intact even as the company operates at a net loss. The structure trades future potential dilution for immediate non-dilutive cash, extending Moderna's financial runway without adding a fixed interest charge to its income statement. For investors tracking Moderna's path to profitability, the key question is whether the capital raised accelerates the pipeline programs needed to close the gap between current operating losses and a return to positive cash generation before the 2032 maturity date.